Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
483.00    2.40 (0.50%)
Bid:
482.80
Ask:
483.80
Spread: 1.00 (0.207%)
Market Cap: £2.49b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Third Quarter Trading Update

15 Feb 2017 07:00

RNS Number : 8892W
QinetiQ Group plc
15 February 2017
 

 

 

 

QinetiQ Group plc

 

Third Quarter Trading Update

 

QinetiQ Group plc ('QinetiQ' or 'the Group') today issues a trading update for the third quarter during which it has made encouraging progress in the implementation of its strategy to drive future growth.

 

Strategy update

 

On 2 December 2016, QinetiQ was awarded a £1bn amendment to its Long Term Partnering Agreement (LTPA) with the UK Ministry of Defence (MOD) which commits approximately half of the core LTPA revenues until 31 March 2028. The Group is already delivering against its commitment to modernise UK air ranges and the Empire Test Pilots' School at MOD Boscombe Down, including the purchase of new aircraft to meet the future training needs of test pilots and aircrew.

 

On 21 December 2016, the Group agreed and completed the acquisition of Meggitt Target Systems. The business, now renamed QinetiQ Target Systems, generates 90 per cent of its revenue from outside the UK and forms part of QinetiQ's International business unit. It will be reported in the Group's Global Products division.

 

On 5 January 2017, the Dragonfire consortium - led by MBDA and including QinetiQ as well as other industry partners - was awarded a £30m programme by the UK MOD to deliver a Laser Directed Energy Weapon (LDEW) Capability Demonstrator. QinetiQ's role is to provide the high-powered laser technology for the programme and conduct trials at various ranges over land and water.

 

Trading update

 

Underlying trading for the Group was as expected during the third quarter.

 

In EMEA Services, revenue under contract for this financial year is similar to the same time last year with resilient margins. As stated previously, the division's performance as a whole is expected to remain steady this year.

 

The Group's Global Products division has shorter order cycles than EMEA Services. Revenue under contract is slightly ahead of this time last year driven by improved order inflow in QinetiQ North America, although the division's performance remains dependent on the timing and shipment of key orders.

 

Balance sheet

 

The incremental capital expenditure associated with the amendment to the LTPA contract is expected to be in the region of £10m this year.

 

The Group is completing the previously announced £50m share repurchase with £13m of the buyback remaining as at 10 Feb 2017.

 

Outlook

Overall, the Board's expectations for Group performance in the current financial year remain unchanged from those set out in QinetiQ's interim results announcement dated 17 November 2016.

 

QinetiQ will announce its preliminary annual results for the year ending 31 March 2017 on 25 May 2017.

 

ENDS

 

Notes to Editors:

 

Download the QinetiQ investor relations app for iPad and iPhone from the App Store.

 

Listed on the London Stock Exchange (LSE: QQ.L), QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. Our customers are predominantly government organisations including defence departments, as well as international customers in other targeted sectors.

 

For more information see www.QinetiQ.com

 

Follow us on twitter @QinetiQ

 

For further information please contact:

Investor relations:

David Bishop, QinetiQ

+44 (0) 7920 108675

Media relations:

Chris Barrie, Citigate Dewe Rogerson

+44 (0) 7968 727289

QinetiQ press office

+44 (0) 1252 393500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDZLFFDLFXBBZ
Date   Source Headline
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSDirectorate Change
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20245:24 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20244:05 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20245:21 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20241:54 pmRNSDirector Declaration
5th Mar 202412:08 pmRNSDirector Declaration
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.